An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
On 18 July 2020, the Malaysian Endocrine and Metabolic Society (MEMS) collaborated with MIMS Education and was supported by Abbott Nutrition to bring the webinar entitled Taking A1ction Now to HCPs, including doctors and pharmacists. The webinar discussed the issues of type 2 diabetes mellitus (T2DM) patients being prone to severe COVID-19 infection and their difficulties in coping with nutrition aspects during the pandemic as well as the role of diabetes-specific nutrition in ensuring T2DM patients thrive during this challenging period.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.